ASXL1	chr20	32358330	32439319	plus	"Defining somatic mutations in acute myeloid leukaemia, myelodysplasia-related. Cytogenetic and molecular abnormalities defining acute myeloid leukaemia, myelodysplasia-related., (WHO, PMID: 35732831)."	"Classification of AML with percentage of blasts required for diagnosis, defined by mutations in ASXL1, BCOR, EZH2, RUNX1, SF3B1, SRSF2, STAG2, U2AF1, or ZRSR2 (ICC, PMID: 35767897)., (ICC, PMID: 35767897)."	NA	NA	Core	Yes	Yes	LOF	"MDS/AML (10-19%), AML (?20% blasts)"	1A	"Optical Genome Mapping detected a [Rearrangements, copy number loss, disrupting insertions, deletions] on chromosome 20 involving the ASXL1 gene with a variant allele frequency of []. ASXL1 mutations frequently occur in myeloid malignancies and are associated with a poor prognosis (PMID: 36068610, 28179279,27069254). ASXL1 mutations in AML were an unfavorable prognostic factor as regards survival (median overall survival 15.9 months vs. 22.3 months; P=0.019), with a significantly lower complete response rate (61% vs. 79.6%; P=0.004) (PMID: 22058207). Mutated ASXL1, BCOR, EZH2, RUNX1, SF3B1, SRSF2, STAG2, U2AF1, and/or ZRSR2 associated with adverse risk category (ELN, PMID: 35797463)."
BCOR	chrX	32358331	40177329	minus	"Defining somatic mutations in acute myeloid leukaemia, myelodysplasia-related. Cytogenetic and molecular abnormalities defining acute myeloid leukaemia, myelodysplasia-related., (WHO, PMID: 35732831)."	"Classification of AML with percentage of blasts required for diagnosis. Defined by mutations in ASXL1, BCOR, EZH2, RUNX1, SF3B1, SRSF2, STAG2, U2AF1, or ZRSR2 (ICC, PMID: 35767897)., (ICC, PMID: 35767897)."	NA	NA	Core	Yes	Yes	LOF	"MDS/AML (10-19%), AML (?20% blasts)"	1A	"Optical Genome Mapping detected a translocation t(X;17)(p11.4;q21.2) or [rearrangement,  loss, insertion, deletion] of BCOR with a variant allele frequency (VAF) of [%].  The t(X;17)(p11.4;q21.2) is a rare, but recurrent variant RARA translocation resulting a BCOR::RARA fusion (PMID: 35797463).  While PML::RARA fusions are considered to have a good prognosis the exact prognosis and response to therapy for variant RARA fusions in unclear.  Correlation with other clinical and pathologic findings is recommended. Mutated ASXL1, BCOR, EZH2, RUNX1, SF3B1, SRSF2, STAG2, U2AF1, and/or ZRSR2 associated with adverse risk category (ELN, PMID: 35797463, 28179279,27069254)."
EZH2	chr7	32358332	148884321	minus	"Defining somatic mutations in acute myeloid leukaemia, myelodysplasia-related; Cytogenetic and molecular abnormalities defining acute myeloid leukaemia, myelodysplasia-related., (WHO, PMID: 35732831)."	"Classification of AML with percentage of blasts required for diagnosis; Defined by mutations in ASXL1, BCOR, EZH2, RUNX1, SF3B1, SRSF2, STAG2, U2AF1, or ZRSR2 (ICC, PMID: 35767897)., (ICC, PMID: 35767897)."	NA	NA	Core	Yes	Yes	LOF	"MDS/AML (10-19%), AML (?20% blasts)"	1A	"Mutated ASXL1, BCOR, EZH2, RUNX1, SF3B1, SRSF2, STAG2, U2AF1, and/or ZRSR2 associated with adverse risk category (ELN, PMID: 35797463)"
GATA2	chr3	32358333	128493201	minus	NA	"Classification of AML with percentage of blasts required for diagnosis; AML with inv(3)(q21.3q26.2) or t(3;3)(q21.3;q26.2)/GATA2; MECOM(EVI1) ? 10%. Hematologic neoplasms with germline predisposition associated with a constitutional disorder affecting multiple organ systems; Myeloid neoplasms with germline GATA2 mutation. Subtypes of myeloid neoplasms associated with germline predisposition; Myeloid neoplasms with germline predisposition and potential organ dysfunction., (ICC, PMID: 35767897)."	NA	NA	Core	Yes	Yes	FUS/GOF	AML	"1A if fused to MECOM, otherwise 3A"	Optical Genome Mapping detected a t(3;3)(q21.3;q26.2). This is a recurrent abnormality resulting in a GATA2::MECOM(EVI1) fusion associated with adverse risk prognosis in the context of AML (PMID: 35797463).
RUNX1	chr21	32358334	36004667	minus	"Acute myeloid leukaemia with defining genetic abnormalities; Acute myeloid leukaemia with RUNX1::RUNX1T1 fusion, (WHO, PMID: 35732831)."	"Classification of AML with percentage of blasts required for diagnosis; AML with t(8;21)(q22;q22.1)/RUNX1::RUNX1T1 ? 10%; Defined by mutations in ASXL1, BCOR, EZH2, RUNX1, SF3B1, SRSF2, STAG2, U2AF1, or ZRSR2, (ICC, PMID: 35767897)."	RUNXT1. MECOM	CBFA2T3	Core	Yes	Yes	GOF	"MDS/AML (10-19%), AML (?20% blasts)"	1A	"Optical Genome Mapping detected a translocation t(8;21)(q22;q22.1) or t(3;21)(q26.2;q22.1) or  t(16;21)(q24.3;q22.1) with a variant allele frequency (VAF) of [%].  t(8;21)(q22;q22.1) or t(3;21)(q26.2;q22.1) are recurrent abnormality resulting in a RUNX1::RUNX1T1  or RUNX1::MECOM fusion.  In the context of AML it is considered to have a favourable prognosis for RUNX1::RUNXT1 fusion and adverse prognosis for RUNX1::MECOM fusion, mainly based on results observed in intensively treated patients. Initial risk assignment may change during the treatment course based on the results from analyses of measurable residual disease. The t(16;21)(q24.3;q22.1) is a rare, recurrent abnormality resulting in a RUNX1::CBFA2T3 fusion that has been included in the most recent International Consensus Classification of Myeloid Neoplasms and, in the context of AML, is considered to be a recurrent genetic entity with an unclear prognosis (PMID: 35767897). Concurrent KIT and/or FLT3 gene mutation does not alter risk categorization. Mutated ASXL1, BCOR, EZH2, RUNX1, SF3B1, SRSF2, STAG2, U2AF1, and/or ZRSR2 associated with adverse risk category (ELN, PMID: 35797463)."
SRSF2	chr17	32358335	76737333	minus	"Defining somatic mutations in acute myeloid leukaemia, myelodysplasia-related; Cytogenetic and molecular abnormalities defining acute myeloid leukaemia, myelodysplasia-related., (WHO, PMID: 35732831)."	"Classification of AML with percentage of blasts required for diagnosis; Defined by mutations in ASXL1, BCOR, EZH2, RUNX1, SF3B1, SRSF2, STAG2, U2AF1, or ZRSR2, (ICC, PMID: 35767897)."	NA	NA	Core	Yes	Yes	LOF	"MDS/AML (10-19%), AML (?20% blasts)"	1A	"Mutated ASXL1, BCOR, EZH2, RUNX1, SF3B1, SRSF2, STAG2, U2AF1, and/or ZRSR2 associated with adverse risk category (ELN, PMID: 35797463)"
STAG2	chrX	32358336	124422664	plus	"Defining somatic mutations in acute myeloid leukaemia, myelodysplasia-related; Cytogenetic and molecular abnormalities defining acute myeloid leukaemia, myelodysplasia-related., (WHO, PMID: 35732831)."	"Classification of AML with percentage of blasts required for diagnosis; Defined by mutations in ASXL1, BCOR, EZH2, RUNX1, SF3B1, SRSF2, STAG2, U2AF1, or ZRSR2, (ICC, PMID: 35767897)."	NA	NA	Core	Yes	Yes	LOF	"MDS/AML (10-19%), AML (?20% blasts)"	1A	"Mutated ASXL1, BCOR, EZH2, RUNX1, SF3B1, SRSF2, STAG2, U2AF1, and/or ZRSR2 associated with adverse risk category (ELN, PMID: 35797463)"
TP53	chr17	32358337	7687538	minus	"Classification and defining features of myelodysplastic neoplasms (MDS).; MDS with biallelic TP53 inactivation (MDS-biTP53). Subtypes of myeloid neoplasms associated with germline predisposition; Myeloid neoplasms with germline predisposition without a pre-existing platelet disorder or organ dysfunction, (WHO, PMID: 35732831)."	"Classification of AML with percentage of blasts required for diagnosis; AML and MDS/AML with mutated TP53† 10-19% (MDS/AML) and ? 20% (AML). Hematologic neoplasms with germline predisposition without a constitutional disorder affecting multiple organ systems; Myeloid or lymphoid neoplasms with germline TP53 mutation. Premalignant clonal cytopenias and myelodysplastic syndromes; Myelodysplastic syndrome with mutated TP53. Premalignant clonal cytopenias and myelodysplastic syndromes; MDS/AML with mutated TP53, (ICC, PMID: 35767897)."	NA	NA	Core	Yes	Yes	LOF	"MDS/AML (10-19%), AML (?20% blasts)"	1A	"Optical Genome Mapping detected a [INSERT REARRANGEMENT TYPE] on chromosome 17 involving the TP53 gene with a variant allele frequency of [].  Loss of function structural variants in TP53 likely have an adverse prognosis (PMID: 28179279,27069254, 35797463)"
ZRSR2	chrX	32358338	15830694	plus	"Defining somatic mutations in acute myeloid leukaemia, myelodysplasia-related; Cytogenetic and molecular abnormalities defining acute myeloid leukaemia, myelodysplasia-related., (WHO, PMID: 35732831)."	"Classification of AML with percentage of blasts required for diagnosis; Defined by mutations in ASXL1, BCOR, EZH2, RUNX1, SF3B1, SRSF2, STAG2, U2AF1, or ZRSR2, (ICC, PMID: 35767897)."	NA	NA	Core	Yes	Yes	LOF	"MDS/AML (10-19%), AML (?20% blasts)"	1A	"Mutated ASXL1, BCOR, EZH2, RUNX1, SF3B1, SRSF2, STAG2, U2AF1, and/or ZRSR2 associated with adverse risk category (ELN, PMID: 35797463)"
